Product Description
ST-1898 is a drug candidate being developed by Scitech Pharma, which acts as a tyrosine kinase inhibitor for the treatment of solid tumors. (Sourced from: http://www.scitech-mq.com.cn/en/contents/1115/1322.html)
Mechanisms of Action: VEGFR2 Inhibitor,C-Met Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Beijing Saite Mingqiang Pharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Melanoma|Renal Cell Carcinoma|Thyroid Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ST-1898-201 | P2 |
Recruiting |
Renal Cell Carcinoma |
2025-12-01 |
|
ST-1898-202 | P2 |
Recruiting |
Thyroid Cancer |
2025-12-01 |
|
ST-1898-203 | P2 |
Recruiting |
Melanoma |
2025-09-01 |
|
CTR20230114 | P2 |
Not yet recruiting |
Renal Cell Carcinoma |
None |